Cite

HARVARD Citation

    Koskenvesa, P. et al. (n.d.). Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response. European journal of haematology. pp. 413-420. [Online]. 
  
Back to record